$9.41
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Needham Initiates Immix Biopharma at Buy With $21 Price Target
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
BofA Initiates Immix Biopharma at Buy With $27 Price Target
Overview
52-week range
$1.94
$12
77% of range
Avg surprise (last 3)
+14.8%
Avg reaction (last 2)
-3.2%
50% positive
Latest IV / EM
98%
EM ±22.3% · $10 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.18 | $-0.21 | +14.3% | -20.0% | -7.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.24 | — | — | — | — | financials |
| Fri Aug 8, 2025 | Jun/2025 | $-0.22 | $-0.21 | -4.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.15 | $-0.23 | +34.8% | — | +1.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.15 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.23 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.24 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Fri Aug 14, 2026 | Jun/2026 | OTHER | -$0.17 | -$0.22 | +22.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-11M | — | $-8M | $-7M | $-5M | — | $-7M | $-5M |
| Net income | $-10M | — | $-8M | $-7M | $-5M | — | $-7M | $-4M |
| EPS (diluted) | $-0.18 | — | $-0.24 | $-0.22 | $-0.15 | — | $-0.24 | $-0.15 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $79M | $94M | $16M | $12M | $16M | $18M | $20M | $24M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $92M | $101M | $17M | $12M | $17M | $20M | $23M | $27M |
| Total assets | $96M | $105M | $20M | $16M | $20M | $23M | $25M | $29M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $11M | $12M | $11M | $10M | $10M | $8M | $5M |
| Total equity | $84M | $94M | — | — | $10M | $13M | $18M | $24M |